Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.


Journal

Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543

Informations de publication

Date de publication:
05 2022
Historique:
received: 30 10 2021
revised: 22 03 2022
accepted: 30 03 2022
pubmed: 12 4 2022
medline: 26 5 2022
entrez: 11 4 2022
Statut: ppublish

Résumé

The LPA gene encodes apolipoprotein (a), a key component of Lp(a), a potent risk factor for cardiovascular disease with no specific pharmacotherapy. Here we describe the pharmacological data for SLN360, a GalNAc-conjugated siRNA targeting LPA, designed to address this unmet medical need. SLN360 was tested in vitro for LPA knockdown in primary hepatocytes. Healthy cynomolgus monkeys received single or multiple subcutaneous doses of the SLN360 sequence ranging from 0.1 to 9.0 mg/kg to determine the pharmacokinetic and pharmacodynamic effects. Liver mRNA and serum biomarker analyses were performed. In vitro, the SLN360 sequence potently reduces LPA mRNA in primary cynomolgus and human hepatocytes, while no effect was observed on the expression of APOB or PLG. In vivo, SLN360 exposure peaks 2 h after subcutaneous injection with near full elimination by 24 h. Specific LPA mRNA reduction (up to 91% 2 weeks after dosing) was observed with only the 3 mg/kg group showing appreciable return to baseline (40%). No consistent dose- or time-dependent effect on the expression of APOB, PLG or a panel of sensitive markers of liver lipid accumulation was observed. Potent (up to 95%) and long lasting (≥9 weeks) serum Lp(a) reduction was observed, peaking in all active groups at day 21. The minimally effective dose was determined to be 0.3 mg/kg with an ED SLN360 induces a sustained reduction in serum Lp(a) levels in cynomolgus monkeys following subcutaneous dosing. SLN360 has potential to address the unmet need of Lp(a) reduction in cardiovascular diseases.

Sections du résumé

BACKGROUND AND AIMS
The LPA gene encodes apolipoprotein (a), a key component of Lp(a), a potent risk factor for cardiovascular disease with no specific pharmacotherapy. Here we describe the pharmacological data for SLN360, a GalNAc-conjugated siRNA targeting LPA, designed to address this unmet medical need.
METHODS
SLN360 was tested in vitro for LPA knockdown in primary hepatocytes. Healthy cynomolgus monkeys received single or multiple subcutaneous doses of the SLN360 sequence ranging from 0.1 to 9.0 mg/kg to determine the pharmacokinetic and pharmacodynamic effects. Liver mRNA and serum biomarker analyses were performed.
RESULTS
In vitro, the SLN360 sequence potently reduces LPA mRNA in primary cynomolgus and human hepatocytes, while no effect was observed on the expression of APOB or PLG. In vivo, SLN360 exposure peaks 2 h after subcutaneous injection with near full elimination by 24 h. Specific LPA mRNA reduction (up to 91% 2 weeks after dosing) was observed with only the 3 mg/kg group showing appreciable return to baseline (40%). No consistent dose- or time-dependent effect on the expression of APOB, PLG or a panel of sensitive markers of liver lipid accumulation was observed. Potent (up to 95%) and long lasting (≥9 weeks) serum Lp(a) reduction was observed, peaking in all active groups at day 21. The minimally effective dose was determined to be 0.3 mg/kg with an ED
CONCLUSIONS
SLN360 induces a sustained reduction in serum Lp(a) levels in cynomolgus monkeys following subcutaneous dosing. SLN360 has potential to address the unmet need of Lp(a) reduction in cardiovascular diseases.

Identifiants

pubmed: 35400495
pii: S0021-9150(22)00162-9
doi: 10.1016/j.atherosclerosis.2022.03.029
pii:
doi:

Substances chimiques

Apolipoproteins A 0
Apolipoproteins B 0
Lipoprotein(a) 0
RNA, Messenger 0
RNA, Small Interfering 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

240-247

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

David A Rider (DA)

Silence Therapeutics GmbH, Robert-Rössle-Straße 10, 13125, Berlin, Germany. Electronic address: d.rider@silence-therapeutics.com.

Mona Eisermann (M)

Silence Therapeutics GmbH, Robert-Rössle-Straße 10, 13125, Berlin, Germany.

Kathrin Löffler (K)

Silence Therapeutics GmbH, Robert-Rössle-Straße 10, 13125, Berlin, Germany.

Manuela Aleku (M)

Silence Therapeutics GmbH, Robert-Rössle-Straße 10, 13125, Berlin, Germany.

Daniel I Swerdlow (DI)

Silence Therapeutics PLC, 72 Hammersmith Road, London, W14 8TH, London, UK.

Sibylle Dames (S)

Silence Therapeutics GmbH, Robert-Rössle-Straße 10, 13125, Berlin, Germany.

Judith Hauptmann (J)

Silence Therapeutics GmbH, Robert-Rössle-Straße 10, 13125, Berlin, Germany.

Eliot Morrison (E)

Silence Therapeutics GmbH, Robert-Rössle-Straße 10, 13125, Berlin, Germany.

Marie Wikström Lindholm (MW)

Silence Therapeutics GmbH, Robert-Rössle-Straße 10, 13125, Berlin, Germany.

Steffen Schubert (S)

Silence Therapeutics GmbH, Robert-Rössle-Straße 10, 13125, Berlin, Germany.

Giles Campion (G)

Silence Therapeutics PLC, 72 Hammersmith Road, London, W14 8TH, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH